Skip to main content
Caplight Logo









Pheast Therapeutics

Pheast Therapeutics

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://www.pheast.com/

Last Round

Series A

Extension

Oct 15, 2025

Total Funding Raised

$100.6M

Company Overview

Pheast Therapeutics is a biotechnology company developing novel innate immune checkpoint inhibitors to enhance macrophage-mediated clearance of tumor cells in aggressive cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cancer immunotherapymonoclonal antibodyantibody-drug conjugateADCCD24solid tumorsbiotech startupclinical trialimmuno-oncologybispecific antibodydrug discoverypharma pipelinebiopharmatargeted therapyclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pheast Therapeutics Comparables

Compare Pheast Therapeutics with similar companies based on industry and business-model similarity.

Pheast Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OncoC4, Inc.
82%
DEM BioPharma
80%
Gilead Sciences
79%

Pheast Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 15, 2025
Series AApr 26, 2022

Key People

Founding team and executive leadership

MD/PhD Amira Barkal

Principal Founder And Interim CEO

Founding Team

Roy Maute

Chief Executive Officer

Executive Team

Pheast Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 26, 2022

    $76M round led by ARCH Venture Partners and Catalio Capital Management.

Pheast Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pheast Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pheast Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range40
Year Founded2021
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?